Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Liposarcoma × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 5 Triple Negative Breast Neoplasms 2 Sarcoma 2 Prostatic Neoplasms 2 Breast Neoplasms 2 Uveal Melanoma 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Platinum-Refractory Fallopian Tube Carcinoma 1 Pancreatic Neoplasms 1 Neoplasms 1 Melanoma 1 Lymphoma 1 Liposarcoma 1 Fallopian Tube Neoplasms 1 Carcinoma, Squamous Cell 1 Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Gemcitabine 2 Docetaxel 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 tanespimycin 1 selinexor 1 pembrolizumab 1 olaparib 1 ixazomib 1 Glutamine 1 Fulvestrant 1 Adjuvants, Pharmaceutic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06116578 2025-12-01

NeoSarc

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Withdrawn

Liposarcoma, Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡